Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
  Top » Catalog » Books » Biology » Cell Biology » Mast Cells: Phenotypic Features, Biological Functions and Role in Immunity Chapters » My Account  |  Cart Contents  |  Checkout   
Quick Find
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
Lobbying the U.S. Government: Background, Issues and Developments
Shopping Cart more
0 items
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
Notifications more
NotificationsNotify me of updates to Presentation, Diagnosis, and Management of Mast Cell Activation Syndrome (pp. 155-232)
Tell A Friend
Tell someone you know about this product.
Presentation, Diagnosis, and Management of Mast Cell Activation Syndrome (pp. 155-232) $0.00
Authors:  (Lawrence B. Afrin, Division of Hematology/Oncology, Medical University of South Carolina, Charleston, SC, USA)
First recognized in 1991 and finally termed such in 2007, “mast cell activation
syndrome” (MCAS) is a large, likely quite prevalent collection of illnesses resulting from
MCs which have been inappropriately activated but which, in contrast to the rare
“mastocytosis,” are not proliferating, or otherwise accumulating, to any significant
extent. Due to the marked diversity of direct and indirect, local and remote biological
effects caused by the plethora of mediators released by MCs, MCAS typically presents as
chronic, persistent or recurrent, waxing and waning or slowly progressive multisystem
polymorbidity generally, but not necessarily, of an inflammatory theme. Suspected to be
of clonal origin in most cases, MCAS usually is acquired relatively early in life via
unknown mechanisms; interaction of environmental factors with inheritable risk factors is
one possibility. Initial manifestations often occur in childhood or adolescence but are
non-specific; in fact, virtually all of the syndrome’s manifestations are non-specific,
leading to decades of mysterious illness (and incorrect diagnoses often poorly responsive
to empiric therapies) prior to diagnosis. A large menagerie of mutations in MC regulatory
elements has been found in MCAS patients; most patients appear to have multiple such
mutations, with no clear patterns, or genotype-phenotype correlations, yet apparent. Such
mutational heterogeneity likely drives the heterogeneity of aberrant MC mediator
expression, in turn causing the extreme heterogeneity of clinical presentation. Different
MCAS patients can present with polar opposite clinical aberrancies. All of the body’s
systems can be affected by MCAS. In addition to clinical heterogeneity, diagnosis is
confounded by difficulty not only in detecting sensitive and specific biomarkers of
primary MC disease but also in finding histologic evidence of a non-proliferative disease
wrought by cells capable of great pleomorphism. For example, in contrast to proliferative
mastocytosis which usually drives significantly elevated tryptase levels, relatively non-
proliferative MCAS usually presents with normal tryptase levels; instead, histamine, MCspecific
prostaglandins, and other mediators need to be assessed in evaluations for
MCAS. Although the World Health Organization 2008 classification scheme for
myeloproliferative neoplasms does not recognize MCAS, proposals for diagnostic criteria
have been published recently and generally require presence of symptoms consistent with
chronic/recurrent aberrant MC mediator release, laboratory evidence of such release (or
of mast cell proliferation not meeting WHO criteria for systemic mastocytosis), absence
of any other evident disease which could better explain the full range of findings in the
patient, and, ideally but not necessarily, at least partial response to therapy targeted
against MCs or MC mediators. Systemic MC disease of any form is not presently curable.
Therapies for MCAS generally aim to control and ameliorate the disease by inhibiting
aberrant mediator production and release, blocking released mediators, and/or managing
the consequences of aberrantly released mediators. Many such therapies are available.
Although there presently is no method to predict which set of therapies will best control
the individual patient’s disease, a methodical, persistent, trial-and-error approach usually
succeeds in finding significantly helpful therapy. Lifespan for most MCAS patients
appears normal, but quality of life can be mildly to severely impaired absent correct
diagnosis and effective treatment. 

Available Options:

  Open Access item.
  Click below PDF icon for free download.


This is an Open Access item. Click above PDF icon for free download.
Special Focus Titles
01.Isoprostanes and Neuroprostanes: Production and Role in Different Pathologies
02.Women and War: Opening Pandora’s Box - Intimate Relationships in the Shadow of Traumatic Experiences
03.Deciphering Organic Foods: A Comprehensive Guide to Organic Food Production, Consumption, and Promotion
04.Developing Critical Thinking: A Multi-Dimensional Approach in the Context of South Africa
05.Photonic Crystals: Characteristics, Performance and Applications
06.Embodied Cognition: Theories and Applications in Education Science
07.Slovenia: Social, Economic and Environmental Issues
08.Chemoradiotherapy: Concurrent Uses, Efficacy and Impact on Prognosis
09.Autism Patents and Beyond
10.Advances in Carcinogenesis Research
11.Digital Stories and Their Integration in Early Childhood and Primary Education: Teaching Scenarios and Practical Ideas
12.Azobenzene: Aspects, Applications and Research

Nova Science Publishers
© Copyright 2004 - 2017

Presentation, Diagnosis, and Management of Mast Cell Activation Syndrome (pp. 155-232)